Publications
2025
Guardamagna, M., S. E. Lochrin, J. W. Smithy, M. Postow, C. Gaudy-Marqueste, N. Malissen, S. Monestier, R. J. Sullivan, J. A. Czapla, A. R. Lawless, I. P. da Silva, G. V. Long, A. M. Menzies, F. Dimitriou, R. Dummer, C. Marchi, A. Chaurand, S. Dalle, P. A. Ascierto, M. Paone, B. A. Facchini, G. Warrier, E. J. Lipson, M. Erdmann, C. Berking, B. Archambaud, S. Roy, E. Routier, C. Boutros, P. Jamme, D. Belkadi-Sadou, N. Simon-Tillaux, and C. Robert. International real-world study of combination immunotherapy sequences in metastatic melanoma. J Immunother Cancer 13, no. 11 (2025). https://dx.doi.org/10.1136/jitc-2025-012225.
Yang, F., S. Y. Lim, I. P. da Silva, L. Yu, J. W. Conway, A. M. Menzies, G. V. Long, J. Y. Yang, and H. Rizos. Circulating IFN gamma-associated protein signatures predict response to neoadjuvant immunotherapy in patients with stage III melanoma. Cancer Cell Int 25, no. 1 (2025): 424. https://dx.doi.org/10.1186/s12935-025-04067-4.
Wu, L., J. M. Wentworth, C. Liddle, N. Fewings, M. Carlino, D. A. Brown, R. Clifton-Bligh, G. V. Long, R. A. Scolyer, N. Norris, S. C. Sasson, V. H. Tsang, A. M. Menzies, and J. E. Gunton. Pancreatic volume and immune biomarkers predict checkpoint inhibitor-associated autoimmune diabetes in humans. J Clin Invest (2025). https://dx.doi.org/10.1172/JCI192938.
da Silva, I. P., L. Zimmer, J. Y. Blay, M. Maio, J. Larkin, M. O. Grimm, S. Puri, M. O. Butler, S. Patel, P. K. Thakkar, G. V. Long, and I. Melero. Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure. ESMO Open 10, no. 11 (2025): 105833. https://dx.doi.org/10.1016/j.esmoop.2025.105833.
Rawson, R. V., N. G. Maher, A. M. Menzies, S. N. Lo, N. M. Ardakani, L. A. Jackett, I. A. Vergara, T. E. Pennington, K. F. Shannon, S. Ch'ng, M. Gonzalez, E. M. Burton, M. W. Lucas, I. L. M. Reijers, E. A. Rozeman, D. E. Gyorki, S. Sandhu, M. S. Carlino, J. Howle, M. Khattak, A. Van der Westhuizen, M. C. Andrews, V. Atkinson, A. C. J. van Akkooi, A. J. Spillane, R. P. M. Saw, B. A. van de Wiel, C. U. Blank, G. V. Long, M. T. Tetzlaff, and R. A. Scolyer. Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma. Ann Oncol (2025). https://dx.doi.org/10.1016/j.annonc.2025.10.1237.
Gouveia, B. M., T. Wong, P. M. Ferguson, A. Glanz, G. Ho, C. Sinz, H. Collgros, L. K. Martin, R. Schwartz, M. A. Sharouni, C. Ramirez, M. P. Senna Santos, B. Gallo, R. A. Scolyer, A. E. Cust, S. N. Lo, and P. Guitera. In vivo cutaneous confocal microscopy for diagnosing the lentigo maligna spectrum: A multicentre prospective study and proposal of a lentigo maligna spectrum score. J Am Acad Dermatol (2025). https://dx.doi.org/10.1016/j.jaad.2025.10.087.
Hong, A. M., T. Wang, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, and G. V. Long. Study protocol of a randomised phase II trial of concurrent stereotactic body radiotherapy with immunotherapy versus immunotherapy alone in patients with 1-5 extracranial melanoma oligometastases (AXIOM). BMC Cancer 25, no. 1 (2025): 1615. https://dx.doi.org/10.1186/s12885-025-15066-z.
Wiggins, J. M., Q. Zhang, Y. Zhang, F. Vand-Rajabpour, D. Hanniford, L. He, Y. Lu, J. M. Kenney, K. D. Sadeghi, D. Argibay, I. Orlow, K. J. Busam, C. Lezcano, T. K. Lee, L. Luo, I. P. Gorlov, C. Amos, M. S. Ernstoff, V. E. Seshan, A. E. Cust, J. Wilmott, R. A. Scolyer, G. J. Mann, A. Reiner, C. E. Kostrzewa, E. Nagore, P. Funchain, J. Ko, S. N. Edmiston, K. Conway, P. B. Googe, D. W. Ollila, J. E. Lee, J. R. Rees, C. L. Thompson, M. Gerstenblith, M. Bosenberg, B. E. Gould Rothberg, I. Osman, Y. Saenger, A. Z. Reynolds, T. Boyce, S. Holmen, S. Yan, E. Brunsgaard, P. Bogner, P. F. Kuan, N. E. Thomas, C. B. Begg, R. Shen, M. Berwick, Y. Shao, D. Polsky, and E. Hernando. Tumor microRNA signatures associate with stage II/III melanoma patient outcomes. Clin Cancer Res (2025). https://dx.doi.org/10.1158/1078-0432.Ccr-24-3785.
Long, G. V., C. Garnett-Benson, S. Dolfi, P. A. Ascierto, J. Guo, A. A. Tarhini, S. Chandra, E. Munoz-Couselo, M. Del Vecchio, A. C. de Melo, M. Callahan, H. Gogas, R. Dummer, D. Schadendorf, P. Koelblinger, G. Quereux, I. Thomas, J. X. Yu, A. Fisher, B. Wang, P. Djidel, A. Chouzy, M. Semaan, B. Chen, A. M. Y. Cheong, and H. A. Tawbi. Adjuvant nivolumab and relatlimab in stage III/IV melanoma: The randomized phase 3 RELATIVITY-098 trial. Nat Med (2025). https://dx.doi.org/10.1038/s41591-025-04032-8.
Varey, A. H., S. N. Lo, R. A. Scolyer, and J. F. Thompson. Predicting sentinel node positivity in melanoma patients: Personalized tools outperform National Comprehensive Cancer Network and American Joint Committee on Cancer-based criteria. J Am Coll Surg 241, no. 5 (2025): 929–30. https://dx.doi.org/10.1097/xcs.0000000000001471.
Vergara, I. A., S. N. Lo, I. Li, J. W. Conway, X. Fu, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, and I. P. da Silva. Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients. Immunooncol Technol (2025): 101078. https://dx.doi.org/10.1016/j.iotech.2025.101078.
Novis, E., M. Rautalin, R. N. Amaria, P. A. Ascierto, C. U. Blank, M. B. Faries, D. J. Grunhagen, D. E. Gyorki, A. J. Hayes, A. M. J. Kuijpers, G. V. Long, J. M. V. Mammen, A. M. Menzies, M. I. Ross, P. Rutkowski, H. A. Tawbi, M. T. Tetzlaff, J. S. Zager, J. A. Wargo, T. J. Hieken, A. C. J. van Akkooi, and the International Neoadjuvant Melanoma Consortium. International survey on evidence for index lymph node surgery after neoadjuvant systemic therapy for stage III melanoma. Ann Surg Oncol (2025). https://dx.doi.org/10.1245/s10434-025-18475-3.
Salam, R. A., K. L. A. Dunlop, T. N. Gide, J. Wilmott, A. Smith, and A. E. Cust. Factors associated with implementation of biomarker testing and strategies to improve its clinical uptake in cancer care: Systematic review using theoretical domains framework. JCO Precis Oncol 9 (2025): e2500063. https://dx.doi.org/10.1200/po-25-00063.
Borgers, J. S. W., D. B. Johnson, E. Livingstone, D. Schadendorf, E. I. Buchbinder, L. E. Haydu, L. Gohil, W. A. Robinson, I. Mehmi, O. Hamid, M. Ferreira, A. K. S. Salama, F. Dimitriou, M. S. Carlino, G. V. Long, P. A. Ascierto, E. Simeone, Y. G. Najjar, G. A. P. Hospers, J. Choi, S. Chandra, J. D. Wayne, C. I. R. Garcia, W. Xu, C. Lebbe, L. Da-Meda, V. Atkinson, M. McKean, A. Forschner, E. A. Asare, A. Daletzakis, J. S. Taylor, F. Amant, K. K. Tsai, Z. Eroglu, J. B. A. G. Haanen, and I. C. Glitza de Oliva. Advanced stage melanoma during pregnancy: Recommendations from a retrospective, multicentre, registry-based study. EClinicalMedicine 89 (2025): 103501. https://dx.doi.org/10.1016/j.eclinm.2025.103501.
Ribas, A., M. M. Milhem, C. J. Hoimes, A. Amin, C. D. Lao, R. M. Conry, J. P. Hunt, G. A. Daniels, M. Almubarak, M. Shaheen, T. Medina, M. Barve, S. Bishnoi, E. Abdi, M. J. Chisamore, C. Guiducci, J. Gomez-Romo, A. Candia, E. Gamelin, R. L. Coffman, R. S. Janssen, and G. V. Long. Phase 2, open-label, multicenter study of nelitolimod in combination with pembrolizumab in anti-PD-1 treatment-naive advanced melanoma. Clin Cancer Res 31, no. 19 (2025): 4070–78. https://dx.doi.org/10.1158/1078-0432.CCR-25-0987.
Versluis, J. M., H. Shehwana, R. Elens, A. M. Menzies, I. L. M. Reijers, P. Dimitriadis, N. G. Maher, A. M. M. van der Veldt, E. Kapiteijn, A. Broeks, R. A. Scolyer, B. A. van de Wiel, A. C. J. van Akkooi, T. N. Schumacher, G. V. Long, and C. U. Blank. Clinical, pathological and molecular characteristics of patients with disease recurrence despite pathologic response to neoadjuvant ipilimumab plus nivolumab in stage III melanoma. Commun Med (Lond) 5, no. 1 (2025): 407. https://dx.doi.org/10.1038/s43856-025-01118-9.
Suann, B., C. Gao, T. Muecke, H. Gim, J. Kovoor, C. Bacchi, W. O. Chan, S. Koneru, P. Kovoor, G. V. Long, J. Thomas, S. Zaman, R. L. Jeffree, and S. Bacchi. Structured curriculum vitae scoring: A possible means to improve female representation in specialty selection? , Intern Med J 55, no. 10 (2025): 1777–78. https://dx.doi.org/10.1111/imj.70213.
Long, G. V., N. Nair, D. Marbach, R. A. Scolyer, S. Wilson, D. Cotting, N. Staedler, R. N. Amaria, P. A. Ascierto, A. A. Tarhini, C. Robert, O. Hamid, C. Gaudy-Marqueste, C. Lebbe, E. Munoz-Couselo, A. M. Menzies, C. Pages, G. Curigliano, M. Mandala, N. Jessop, U. Bader, M. Perdicchio, V. Teichgraber, M. Muecke, C. Markert, and C. Blank. Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: The randomized phase 1b/2 Morpheus-Melanoma trial. Nat Med (2025). https://dx.doi.org/10.1038/s41591-025-03967-2.
Boutros, A., A. M. Taylor, I. Li, N. A. Adegoke, T. Wong, A. H. R. Varey, K. F. Shannon, S. Ch'ng, R. P. M. Saw, T. Pennington, J. Stretch, A. Spillane, A. C. J. van Akkooi, R. A. Scolyer, I. P. da Silva, M. S. Carlino, G. V. Long, S. N. Lo, and A. M. Menzies. A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma. Eur J Cancer 229 (2025): 115782. https://dx.doi.org/10.1016/j.ejca.2025.115782.
Regan, M. M., P. Ascierto, E. J. Lipson, J. Palaia, A. Moshyk, A. Selvan, C. D. Lao, M. Atkins, D. F. McDermott, R. Potluri, S. Ranjan, S. Bilthare, G. V. Long, F. Stephen Hodi, H. Tawbi, and D. Schadendorf. Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. J Immunother Cancer 13, no. 9 (2025). https://dx.doi.org/10.1136/jitc-2025-012747.
Cai, Z., E. L. Boys, Z. Noor, A. T. Aref, D. Xavier, N. Lucas, S. G. Williams, J. M. S. Koh, R. C. Poulos, Y. Wu, M. Dausmann, K. L. MacKenzie, A. Aguilar-Mahecha, C. Armengol, M. M. Barranco, M. Basik, E. D. Bowman, R. Clifton-Bligh, E. A. Connolly, W. A. Cooper, B. Dalal, A. DeFazio, M. Filipits, P. J. Flynn, J. D. Graham, J. George, A. J. Gill, M. Gnant, R. Habib, C. C. Harris, K. Harvey, L. G. Horvath, C. Jackson, M. R. J. Kohonen-Corish, E. Lim, J. J. Liu, G. V. Long, R. V. Lord, G. J. Mann, G. W. McCaughan, L. Morgan, L. Murphy, S. Nagabushan, A. Nagrial, J. Navines, B. J. Panizza, J. S. Samra, R. A. Scolyer, J. Souglakos, A. Swarbrick, D. Thomas, R. L. Balleine, P. G. Hains, P. J. Robinson, Q. Zhong, and R. R. Reddel. Federated deep learning enables cancer subtyping by proteomics. Cancer Discov 15, no. 9 (2025): 1803–18. https://dx.doi.org/10.1158/2159-8290.CD-24-1488.
Lipson, E. J., S. Dolfi, H. Tang, H. A. Tawbi, F. Medina-Soto, E. Castillo Gutierrez, P. Rutkowski, H. Gogas, E. Murillo, P. A. Ascierto, K. Desai, M. Maio, K. Demers, A. Mazzei, S. Keidel, K. Miller-Moslin, J. X. Yu, F. S. Hodi, D. Schadendorf, G. V. Long, and C. Garnett-Benson. Unraveling relatlimab-specific biology using biomarker analyses in patients with advanced melanoma in RELATIVITY-047. Clin Cancer Res 31, no. 17 (2025): 3702–14. https://dx.doi.org/10.1158/1078-0432.CCR-24-2499.
Vergara, I. A., N. G. Maher, A. J. Potter, E. C. Paver, J. W. Conway, S. N. Lo, A. J. Colebatch, G. V. Long, J. S. Wilmott, and R. A. Scolyer. Discovery and validation of an ancillary genomic test of malignancy for primary melanocytic tumors. Clin Cancer Res 31, no. 17 (2025): 3742–53. https://dx.doi.org/10.1158/1078-0432.CCR-24-1902.
Clarke, E. L., D. Magee, J. Newton-Bishop, W. Merchant, R. Insall, N. G. Maher, R. A. Scolyer, G. Farnworth, A. Ali, S. O'Shea, and D. Treanor. The development and evaluation of a convolutional neural network for cutaneous melanoma detection in whole slide images. Arch Pathol Lab Med 149, no. 9 (2025): 831–37. https://dx.doi.org/10.5858/arpa.2024-0094-OA.
Johnson, R., M. Gonzalez, M. Rosano, S. Coburn, K. Linke, G. V. Long, G. McArthur, A. Menzies, T. Pennington, M. Lyle, L. Gent, K. White, and M. Krishnasamy. Development of a mapping framework to define specialist clinical practice nursing roles within melanoma treatment settings. Cancer Nursing 48, no. 5S (2025): S50–S50. <Go to ISI>://WOS:001560745600122.
Arance, A., M. A. Berciano-Guerrero, J. Guo, M. S. Carlino, P. A. Ascierto, M. Burotto, L. Mortier, P. Queirolo, V. Chiarion-Sileni, J. Schachter, X. Zhang, J. Martin-Liberal, M. Del Vecchio, C. E. Okpara, C. Dutcus, J. Zhang, S. J. Diede, T. Neff, and G. V. Long. Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. Ann Oncol (2025). https://dx.doi.org/10.1016/j.annonc.2025.08.008.
Menzer, C., S. Dugas-Breit, M. Dugas, C. U. Blank, E. J. Groen, I. Reijers, M. Schlaak, J. Eckardt, K. P. M. Suijkerbuijk, L. Zimmer, D. B. Johnson, C. Franklin, F. Meiss, B. Schilling, F. Meier, R. Gutzmer, K. M. Thoms, T. Haalck, M. Muller, A. Kopp-Schneider, M. S. Carlino, G. V. Long, A. M. Menzies, A. A. M. van der Veldt, J. W. B. de Groot, T. Eigentler, M. Stevense-den Boer, C. Pfohler, K. Herbschleb, and J. C. Hassel. Targeted therapy for rare BRAF-mutated melanoma: Updated multicenter analysis and launch of a publicly accessible online outcome database. Eur J Cancer 228 (2025): 115703. https://dx.doi.org/10.1016/j.ejca.2025.115703.
Hong, A. M., S. N. Lo, G. B. Fogarty, J. Stretch, W. Wang, P. Fernandez-Penas, R. C. W. Martin, M. Foote, H. P. Soyer, J. Ruben, V. Mar, L. Rocha, C. Festa-Neto, C. Wratten, S. Hogarth, H. Collgros, A. Glanz, B. M. Gouveia, R. A. Scolyer, M. T. King, and P. Guitera. Radiotherapy versus imiquimod for complex lentigo maligna: A phase 3 randomized clinical trial. J Am Acad Dermatol 93, no. 5 (2025): 1251–60. https://dx.doi.org/10.1016/j.jaad.2025.07.028.
Boutros, A., A. Idan, S. Sleiman, F. Bacha, T. Zhang, V. Jayadev, A. M. Menzies, G. V. Long, and D. J. Handelsman. Testicular function after immune-checkpoint inhibitors treatment. Clin Endocrinol (Oxf) 103, no. 5 (2025): 721–28. https://dx.doi.org/10.1111/cen.70001.
Long, G. V., H. Tang, K. Desai, S. Wang, M. Del Vecchio, J. Larkin, C. Ritchings, S. P. Huang, J. Baden, D. Balli, H. Chang, G. Fusaro, D. Tenney, S. Dolfi, and J. Weber. Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915. J Immunother Cancer 13, no. 7 (2025). https://dx.doi.org/10.1136/jitc-2025-012034.
Aung, T. N., M. Liu, D. Su, S. Shafi, C. Boyaci, S. Steen, N. Tsiknakis, J. M. Vidal, N. Maher, G. Micevic, S. X. Tan, M. D. Vesely, S. Nourmohammadi, Y. Bai, D. Djureinovic, P. F. Wong, K. Bates, N. N. N. Chan, N. Gavirelatou, M. He, S. Burela, R. Barna, M. Bosic, K. Bräutigam, I. Illabochaca, Z. Chenhao, J. Gama, B. Kreis, R. Mohacsi, N. Pillar, J. Pinto, C. Poulios, M. A. Toli, E. Tzoras, Y. Bracero, F. Bosisio, G. Cserni, A. Dema, F. Fortarezza, M. S. Gonzalez, I. Gullo, F. J. Queipo Gutiérrez, E. Hacihasanoglu, V. Jovic, B. Lazar, M. Olinca, C. Neppl, R. C. Oliveira, F. Pezzuto, D. Gomes Pinto, V. Plotar, O. Pop, T. Rau, K. Skok, W. Sun, E. D. Serbes, W. Solass, O. Stanowska, M. Szasz, K. Szymonski, F. Thimm, D. Vignati, A. Vigdorovits, V. Prieto, T. Sinnberg, J. Wilmott, S. Cowper, J. Warrell, Y. Saenger, J. Hartman, J. Plummer, I. Osman, D. L. Rimm, and B. Acs. Pathologist-read vs AI-driven assessment of tumor-infiltrating lymphocytes in melanoma. JAMA Netw Open 8, no. 7 (2025): e2518906. https://dx.doi.org/10.1001/jamanetworkopen.2025.18906.
Puhr, R., E. G. Ryan, D. L. Couturier, A. C. J. van Akkooi, I. P. da Silva, S. Heritier, and S. N. Lo. Transforming clinical trials in skin cancer research: Exploring the potential of flexible and innovative designs. J Invest Dermatol 145, no. 7 (2025): 1569–79. https://dx.doi.org/10.1016/j.jid.2025.03.032.
Wijnen, S. C. M. A., P. Dimitriadis, I. L. M. Reijers, A. M. Menzies, G. V. Long, L. F. A. Wessels, and C. U. Blank. Dissecting response to neoadjuvant immunotherapy-treated melanoma using cancer-immunity cycle-associated signatures. Cancer Immunol Immunother 74, no. 8 (2025): 253. https://dx.doi.org/10.1007/s00262-025-04094-0.
Braden, J., J. W. Conway, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. Do BRAF-targeted therapies have a role in the era of immunotherapy? , ESMO Open 10, no. 7 (2025): 105314. https://dx.doi.org/10.1016/j.esmoop.2025.105314.
Wong, T., S. Ch'ng, P. Ferguson, L. Martin, A. M. Menzies, I. P. da Silva, G. V. Long, R. A. Scolyer, A. C. J. van Akkooi, and S. N. Lo. Predictive performance of the clinicopathologic gene expression profile (CP-GEP) in identifying cutaneous melanoma patients for whom sentinel lymph node biopsy is unnecessary: A systematic review and meta-analysis. Crit Rev Oncol Hematol 214 (2025): 104816. https://dx.doi.org/10.1016/j.critrevonc.2025.104816.
Chan, W. Y., A. Stewart, R. J. Diefenbach, E. S. Gray, J. H. Lee, R. A. Scolyer, G. V. Long, and H. Rizos. Pre-amplification of cell-free DNA: Balancing amplification errors with enhanced sensitivity. Biomolecules 15, no. 6 (2025). https://dx.doi.org/10.3390/biom15060883.
Mandala, M., T. Amaral, P. Rutkowski, M. C. Sergi, M. L. Rasch, N. Benannoune, P. Serra, M. G. Vitale, D. Giannarelli, A. M. Arance, E. M. Couselo, B. Neyns, I. Dirven, M. Tucci, M. Guida, F. Spagnolo, E. Rossi, P. Queirolo, P. Quaglino, R. Depenni, J. Placzke, A. M. D. Giacomo, M. Del Vecchio, A. Indini, I. P. da Silva, A. M. Menzies, A. Hong, P. Lorigan, G. V. Long, C. Robert, and P. A. Ascierto. Combined immunotherapy with nivolumab and ipilimumab with and without sequential or concomitant stereotactic radiotherapy in patients with melanoma brain metastasis: An international retrospective study. Eur J Cancer 225 (2025): 115567. https://dx.doi.org/10.1016/j.ejca.2025.115567.
Thompson, J. F., R. F. Uren, K. London, D. Chung, R. P. Saw, A. J. Spillane, J. R. Stretch, K. F. Shannon, J. Howle, O. E. Nieweg, S. Ch'ng, T. E. Pennington, A. J. Potter, R. A. Scolyer, and G. J. Williams. Nodal radioactivity after lymphoscintigraphy as a guide to sentinel node-positivity in melanoma patients. Eur J Surg Oncol 51, no. 9 (2025): 110225. https://dx.doi.org/10.1016/j.ejso.2025.110225.
Wu, L., V. Tsang, R. Clifton-Bligh, M. S. Carlino, T. Tse, Y. Huang, M. Oatley, N. W. Cheung, G. V. Long, A. M. Menzies, and J. Gunton. Hyperglycemia in patients treated with immune checkpoint inhibitors: Key clinical challenges and multidisciplinary consensus recommendations. J Immunother Cancer 13, no. 6 (2025). https://dx.doi.org/10.1136/jitc-2024-011271.
Lipson, E. J., F. Stephen Hodi, H. Tawbi, D. Schadendorf, P. A. Ascierto, L. Matamala, E. C. Gutierrez, P. Rutkowski, H. J. Gogas, C. D. Lao, J. J. Menezes, S. Dalle, A. Arance, C. Gaudy-Marqueste, B. Chen, W. Jackson, S. Mukherjee, S. Dolfi, and G. V. Long. Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update. Eur J Cancer 225 (2025): 115547. https://dx.doi.org/10.1016/j.ejca.2025.115547.
Fletcher, K., M. Machaalani, R. El Hajj Chehade, A. H. Nassar, R. Nawfal, M. Manos, A. M. Menzies, F. Aboubakar-Nana, J. C. Hassel, D. J. Pinato, A. Johnson, A. C. Olsson-Brown, M. S. Carlino, A. Malgeri, A. Cortellini, A. Singh, K. Parikh, S. Y. Kim, A. R. Naqash, G. V. Long, P. Challa, T. K. Choueiri, E. Sharon, S. Shah, and D. B. Johnson. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open 8, no. 6 (2025): e2513727. https://dx.doi.org/10.1001/jamanetworkopen.2025.13727.
Lo, S. N., C. Gjorup, A. H. Chakera, L. R. Hölmich, M. Moncrieff, A. MacKenzie Ross, O. Cassell, J. Ma, M. B. Weitemeyer, R. Olofsson Bagge, S. Klausen, V. F. Calsavara, J. P. Duprat Neto, E. Bertolli, S. Ch'ng, R. P. M. Saw, K. F. Shannon, A. J. Spillane, O. E. Nieweg, J. R. Stretch, G. J. Mann, J. L. C. Geh, L. E. Haydu, R. C. W. Martin, C. Sharon, G. C. Karakousis, M. Kashani-Sabet, G. Adigbli, M. A. El Sharouni, J. E. Gershenwald, R. A. Scolyer, J. F. Thompson, and A. H. R. Varey. Global applicability of a risk prediction tool for sentinel node positivity in patients with primary cutaneous melanoma. JAMA Dermatol 161, no. 6 (2025): 589–96. https://dx.doi.org/10.1001/jamadermatol.2025.0318.
Menzies, A. M., G. V. Long, A. Kohn, H. Tawbi, J. Webe, K. Flaherty, G. A. McArthur, P. A. Ascierto, Y. Pfluger, K. Lewis, K. K. Tsai, O. Hamid, H. Prenen, L. Fein, E. Wang, C. Guenzel, F. Zhang, J. F. Kleh, A. di Pietro, and M. A. Davies. A plain language summary of POLARIS: A study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future Oncol 21, no. 14 (2025): 1703–11. https://dx.doi.org/10.1080/14796694.2025.2495540.
Fletcher, K. A., R. S. Goodman, A. Lawless, R. Woodford, F. Fa'ak, A. Tipirneni, J. R. Patrinely, H. L. Yeoh, S. Rapisuwon, A. Haydon, I. Osman, J. M. Mehnert, G. V. Long, R. J. Sullivan, M. S. Carlino, A. M. Menzies, A. K. Dewan, and D. B. Johnson. Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors. JAMA Dermatol 161, no. 5 (2025): 555–57. https://dx.doi.org/10.1001/jamadermatol.2025.0025.
Novis, E., J. Tan, D. Vignati, T. Wong, R. V. Rawson, J. R. Stretch, S. N. Lo, T. E. Pennington, S. Ch'ng, K. F. Shannon, A. J. Spillane, O. E. Nieweg, J. F. Thompson, M. Rtshiladze, R. A. Scolyer, and R. P. M. Saw. Cartilage resection in the surgical management of ear melanoma. Ann Surg Oncol 32, no. 7 (2025): 5306–14. https://dx.doi.org/10.1245/s10434-025-17294-w.
Syeda, M. M., G. V. Long, J. Garrett, V. Atkinson, M. Santinami, D. Schadendorf, A. Hauschild, M. Millward, M. Mandala, V. Chiarion-Sileni, M. Smylie, G. M. Manikhas, R. Dummer, J. M. Wiggins, S. Ali, S. B. Adnaik, M. Tan, M. Dajee, and D. Polsky. Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): A biomarker analysis from a double-blind, randomised phase 3 trial. Lancet Oncol 26, no. 5 (2025): 641–53. https://dx.doi.org/10.1016/S1470-2045(25)00139-1.
Braden, J., A. Potter, R. V. Rawson, N. A. Adegoke, S. N. Lo, J. W. Conway, A. M. Menzies, M. S. Carlino, G. Au-Yeung, R. P. M. Saw, A. J. Spillane, K. F. Shannon, T. E. Pennington, S. Ch'ng, D. E. Gyorki, J. R. Howle, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. Longitudinal analysis reveals dynamic changes in histopathologic features in responders to neoadjuvant treatment in a stage III BRAF-mutant melanoma cohort. Mod Pathol 38, no. 8 (2025): 100776. https://dx.doi.org/10.1016/j.modpat.2025.100776.
Grover, P., S. N. Lo, I. Li, A. M. J. Kuijpers, F. Kreidieh, A. Williamson, T. Amaral, F. Dimitriou, J. Placzke, K. Olino, M. G. Vitale, P. Saiag, R. Gutzmer, C. Allayous, R. Olofsson Bagge, J. Mattsson, N. Asher, T. J. Carter, T. M. Meniawy, A. R. Lawless, J. A. Czapla, L. Warburton, C. Gaudy-Marqueste, J. J. Grob, R. G. Collins, E. Zhang, J. I. Kessels, B. Neyns, I. Mehmi, O. Hamid, M. Julve, A. J. S. Furness, K. A. Margolin, S. Lev-Ari, J. M. Ressler, W. Haque, M. A. Khattak, A. Wicky, R. Roberts-Thomson, A. Arance, G. Warrier, M. D. Schollenberger, P. Parente, E. Chatziioannou, E. J. Lipson, O. Michielin, J. S. Weber, C. Hoeller, J. Larkin, M. B. Atkins, R. Essner, D. B. Johnson, R. J. Sullivan, P. Nathan, J. Schachter, C. Lebbe, P. A. Ascierto, H. Kluger, P. Rutkowski, R. Dummer, C. Garbe, P. C. Lorigan, E. Burton, H. A. Tawbi, J. Haanen, M. S. Carlino, A. M. Menzies, and G. V. Long. Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma. Ann Oncol 36, no. 7 (2025): 807–18. https://dx.doi.org/10.1016/j.annonc.2025.03.021.
Duncan, L. M., D. E. Elder, M. W. Piepkorn, S. R. Knezevich, W. A. M. Blokx, M. Bosenberg, K. J. Busam, R. Carr, M. G. Cook, P. Gerami, J. Ko, G. Landman, A. J. Lazar, L. Lowe, D. Mihic-Probst, B. Schmidt, C. R. Shea, R. A. Scolyer, X. Xu, J. G. Elmore, and R. L. Barnhill. Shifts in cutaneous melanocytic tumor diagnostic terminology: Melanocytoma, mpath-dx v2.0 and the WHO skin5. J Cutan Pathol (2025). https://dx.doi.org/10.1111/cup.14788.
Jackett, L. A., C. Mitchell, C. Snell, C. Hewitt, S. Yellenki, H. Snow, D. Speakman, C. Angel, C. Khoo, J. M. Pang, S. N. Lo, R. A. Scolyer, S. Fox, and D. Gyorki. Molecular analysis of cutaneous sarcomatoid neoplasms frequently identifies melanoma driver variants. Am J Surg Pathol 49, no. 7 (2025): 650–57. https://dx.doi.org/10.1097/pas.0000000000002390.
Stekelenburg, I., A. E. Laeijendecker, R. C. van Doorn, A. Doeksen, W. A. M. Blokx, Y. M. Schrage, A. C. J. van Akkooi, R. A. Scolyer, E. L. Postma, and M. A. E. Sharouni. Reconsidering the surgical approach in cutaneous melanoma: Does wide local excision after a complete diagnostic excision reduce the risk of recurrence? , Eur J Cancer 220 (2025): 115366. https://dx.doi.org/10.1016/j.ejca.2025.115366.
Bührer, E., N. Glassee, M. Kicinski, O. J. Kennedy, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, S. Gandini, S. Valpione, S. Suciu, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. EJC Skin Cancer 3, no. 100727 (2025): 100727. https://dx.doi.org/10.1016/j.ejcskn.2025.100727.
Lai, B., H. P. Soyer, L. Zhu, P. M. Ferguson, B. O'Brien, T. Dodds, R. A. Scolyer, G. Ferrara, and K. J. L. Bell. The impact of providing clinical images and dermoscopy reports on the diagnosis of melanocytic skin lesions. J Eur Acad Dermatol Venereol 39, no. 7 (2025): e634–e37. https://dx.doi.org/10.1111/jdv.20655.
Zhou, L., M. Barros, E. Hsiao, Z. Eroglu, S. Sandhu, I. Samoylenko, S. N. Lo, M. S. Carlino, G. Au-Yeung, M. Gonzalez, A. J. Spillane, T. E. Pennington, K. F. Shannon, R. Kapoor, E. M. Burton, H. A. Tawbi, R. N. Amaria, C. U. Blank, J. P. Duprat, R. Brito de Paula, D. E. Gyorki, R. P. M. Saw, S. Ch'Ng, R. V. Rawson, R. A. Scolyer, I. P. da Silva, A. C. J. van Akkooi, G. V. Long, and A. M. Menzies. FDG-PET associations with pathological response and survival with neoadjuvant immunotherapy for melanoma. J Immunother Cancer 13, no. 3 (2025). https://dx.doi.org/10.1136/jitc-2025-011483.
Luke, J. J., P. A. Ascierto, M. A. Khattak, P. Rutkowski, M. Del Vecchio, F. Spagnolo, J. Mackiewicz, L. C. Merino, V. Chiarion-Sileni, J. M. Kirkwood, C. Robert, D. Schadendorf, F. de Galitiis, M. S. Carlino, R. Dummer, P. Mohr, A. Odeleye-Ajakaye, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, and G. V. Long. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer 220 (2025): 115381. https://dx.doi.org/10.1016/j.ejca.2025.115381.
Kirkwood, J. M., P. Mohr, C. Hoeller, J. J. Grob, M. Del Vecchio, J. Lord-Bessen, S. Srinivasan, A. Nassar, F. Campigotto, H. Fairbanks, F. Taylor, R. Lawrance, G. V. Long, and J. Weber. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. Eur J Cancer 220 (2025): 115371. https://dx.doi.org/10.1016/j.ejca.2025.115371.
Weber, J., W. Haque, S. N. Markovic, A. K. S. Salama, I. Mehmi, R. J. Sullivan, Y. G. Najjar, A. C. J. van Akkooi, A. M. Menzies, G. V. Long, A. M. Taylor, J. Haanen, L. P. Zijlker, K. L. Davis, S. Karanth, D. Norton, and L. Connolly. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist 30, no. 3 (2025). https://dx.doi.org/10.1093/oncolo/oyae289.
Guan, A., and C. Quek. Single-cell multi-omics: Insights into therapeutic innovations to advance treatment in cancer. Int J Mol Sci 26, no. 6 (2025). https://dx.doi.org/10.3390/ijms26062447.
Nassar, A. H., S. Abou Alaiwi, T. El Zarif, R. Denu, W. Macaron, N. Abdel-Wahab, D. Freeman, A. Vasbinder, S. Hayeck, E. Anderson, R. S. Goodman, D. B. Johnson, S. Grynberg, R. Shapira, J. M. Kwan, R. Woodford, G. V. Long, T. Haykal, S. Dent, Y. Kojima, K. Yonemor, A. Tandon, A. Trevino, N. Akhter, E. H. Yang, G. Hui, A. Drakaki, E. El-Am, E. Kozaily, A. Al-Hader, E. Bou Farhat, P. Babu, A. Mittra, M. Li, N. Jones, J. Baena, M. Juarez Herrera, S. Foderaro, F. A. Nana, C. Kim, P. Sackstein, K. Parikh, A. P. Desai, C. Smith, A. Cortellini, D. J. Pinato, J. Korolewicz, N. Lopetegui-Lia, P. Funchain, A. Choudhary, A. Asnani, V. Navani, D. Meyers, I. Stukalin, J. A. Ocejo Gallegos, J. Trent, S. Nusrat, C. Malvar, R. R. McKay, T. G. Neilan, T. K. Choueiri, and A. R. Naqash. Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: A multicenter international retrospective study. J Immunother Cancer 13, no. 3 (2025). https://dx.doi.org/10.1136/jitc-2024-009364.
Long, G. V., E. Shklovskaya, L. Satgunaseelan, Y. Mao, I. P. da Silva, K. A. Perry, R. J. Diefenbach, T. N. Gide, B. Shivalingam, M. E. Buckland, M. Gonzalez, N. Caixeiro, I. A. Vergara, X. Bai, R. V. Rawson, E. Hsiao, U. Palendira, T. G. Phan, A. M. Menzies, M. S. Carlino, C. Quek, S. M. Grimmond, J. H. A. Vissers, D. Yeo, J. E. J. Rasko, M. Khasraw, B. Neyns, D. A. Reardon, D. M. Ashley, H. Wheeler, M. Back, R. A. Scolyer, J. Drummond, J. S. Wilmott, and H. Rizos. Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. Nat Med 31, no. 5 (2025): 1557–66. https://dx.doi.org/10.1038/s41591-025-03512-1.
Long, G. V., V. Atkinson, S. N. Lo, A. D. Guminski, S. K. Sandhu, M. P. Brown, M. Gonzalez, G. A. McArthur, and A. M. Menzies. Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study. Lancet Oncol 26, no. 3 (2025): 320–30. https://dx.doi.org/10.1016/S1470-2045(24)00735-6.
Sheriff, S., M. Saba, R. Patel, G. Fisher, T. Schroeder, G. Arnolda, D. Luo, L. Warburton, E. Gray, G. V. Long, J. Braithwaite, H. Rizos, and L. A. Ellis. A scoping review of factors influencing the implementation of liquid biopsy for cancer care. J Exp Clin Cancer Res 44, no. 1 (2025): 50. https://dx.doi.org/10.1186/s13046-025-03322-w.
Kennedy, O. J., N. Glassee, M. Kicinski, E. Bührer, S. Valpione, S. Gandini, S. Suciu, C. U. Blank, G. V. Long, V. G. Atkinson, S. Dalle, A. M. Haydon, A. Meshcheryakov, A. Khattak, M. S. Carlino, S. Sandhu, J. Larkin, S. Puig, P. A. Ascierto, P. Rutkowski, D. Schadendorf, M. Boers-Sonderen, A. M. Di Giacomo, A. J. M. van den Eertwegh, J. J. Grob, R. Gutzmer, R. Jamal, A. C. J. van Akkooi, C. Robert, A. M. M. Eggermont, P. Lorigan, and M. Mandala. Prognostic and predictive importance of body mass index and type 2 diabetes in the European organisation for research and treatment of cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. EJC Skin Cancer 3, no. 100284 (2025): 100284. https://dx.doi.org/10.1016/j.ejcskn.2025.100284.
Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell 43, no. 3 (2025): 563. https://dx.doi.org/10.1016/j.ccell.2025.01.011.
Lo, S. N., G. J. Williams, A. E. Cust, D. W. Ollila, A. H. R. Varey, S. Ch'ng, R. A. Scolyer, and J. F. Thompson. Risk of death due to melanoma and other causes in patients with thin cutaneous melanomas. JAMA Dermatol 161, no. 2 (2025): 167–74. https://dx.doi.org/10.1001/jamadermatol.2024.4900.
Munoz-Couselo, E., A. Soria Rivas, S. Sandhu, G. V. Long, M. F. Sanmamed, A. Spreafico, E. Buchbinder, M. Sznol, H. Prenen, A. Fedenko, M. Milhem, A. M. Arance Fernandez, J. J. Grob, L. Demidov, C. Robert, C. Habigt, S. Evers, N. Sleiman, D. Dejardin, C. Ardeshir, N. Martin, C. Boetsch, J. Charo, V. Teichgraber, A. Kraxner, N. Keshelava, and O. Bechter. Phase Ib study of immunocytokine simlukafusp alfa (FAP-IL2v) combined with pembrolizumab for treatment of advanced and/or metastatic melanoma. Cancer Res Commun 5, no. 2 (2025): 358–68. https://dx.doi.org/10.1158/2767-9764.CRC-24-0601.
Yoon, C. H., M. I. Ross, B. R. Gastman, J. J. Luke, P. A. Ascierto, G. V. Long, P. Rutkowski, M. Khattak, M. Del Vecchio, L. de la Cruz Merino, J. Mackiewicz, V. Chiarion-Sileni, D. Schadendorf, M. S. Carlino, Y. Zhao, M. Fukunaga-Kalabis, C. Krepler, A. M. M. Eggermont, J. E. Gershenwald, and V. K. Sondak. Adjuvant pembrolizumab in stage II melanoma: Outcomes by primary tumor location in the randomized, double-blind, phase III KEYNOTE-716 trial. Ann Surg Oncol 32, no. 4 (2025): 2756–64. https://dx.doi.org/10.1245/s10434-024-16642-6.
Mo, J., A. Zaremba, A. J. Inderjeeth, P. El Zeinaty, A. Li, A. Wicky, N. Della Marta, C. G. Marqueste, A. S. Bohne, M. Matias, N. McNamee, L. Festino, C. Chen, S. Ch'ng, A. C. J. van Akkooi, L. D. Meda, J. J. Park, P. A. Ascierto, A. Hauschild, J. H. Lee, J. J. Grob, J. Mangana, A. Guminski, O. Michielin, W. Xu, C. Lebbe, S. Sandhu, L. Zimmer, A. M. Menzies, S. N. Lo, G. V. Long, M. S. Carlino, and I. P. da Silva. Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel cell carcinoma. Eur J Cancer 217 (2025): 115254. https://dx.doi.org/10.1016/j.ejca.2025.115254.
Quek, C. Harnessing molecular insights for translational impact: Highlights from the special issue titled "New Insights in Translational Bioinformatics". Int J Mol Sci 26, no. 2 (2025). https://dx.doi.org/10.3390/ijms26020579.
Dummer, R., C. Robert, R. A. Scolyer, J. M. Taube, M. T. Tetzlaff, A. M. Menzies, A. Hill, J. J. Grob, D. C. Portnoy, C. Lebbe, M. A. Khattak, J. Cohen, G. Bar-Sela, I. Mehmi, R. Shapira-Frommer, N. Meyer, A. L. Webber, Y. Ren, M. Fukunaga-Kalabis, C. Krepler, and G. V. Long. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: A phase 1/2 trial. Nat Med 31, no. 1 (2025): 144–51. https://dx.doi.org/10.1038/s41591-024-03411-x.
Hauschild, A., C. Garbe, P. A. Ascierto, L. Demidov, B. Dreno, R. Dummer, A. Eggermont, A. M. Forsea, C. Gebhardt, J. E. Gershenwald, O. Hamid, C. Hoeller, L. Kandolf, R. Kaufmann, J. M. Kirkwood, C. Lebbe, G. V. Long, J. Malvehy, S. Martin-Algarra, G. McArthur, B. Neyns, E. Richtig, C. Robert, D. Schadendorf, R. A. Scolyer, V. K. Sondak, A. Wainstein, M. Weichenthal, P. Nuti, and the Melanoma World Society Study Group. Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: An international survey. Lancet Oncol 26, no. 1 (2025): 12–14. https://dx.doi.org/10.1016/S1470-2045(24)00627-2.
Lo, S. N., G. J. Williams, A. E. Cust, A. H. R. Varey, S. Ch'ng, R. A. Scolyer, and J. F. Thompson. Long-term survival across Breslow thickness categories: Findings from a population-based study of 210,042 Australian melanoma patients. J Natl Cancer Inst 117, no. 1 (2025): 152–56. https://dx.doi.org/10.1093/jnci/djae198.
Sturm, R. A., D. J. Smit, D. L. Duffy, C. McLean, R. A. Scolyer, G. A. McArthur, A. T. Papenfuss, M. S. Stark, H. P. Soyer, and V. J. Mar. Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma. Br J Dermatol 192, no. 1 (2024): 55–62. https://dx.doi.org/10.1093/bjd/ljae336.
Wu, Z., B. Nickel, F. Boroumand, D. Elder, P. M. Ferguson, R. A. Scolyer, B. O'Brien, R. Barnhill, A. S. Adamson, A. C. J. van Akkooi, J. Emery, L. Parker, D. Low, C. Low, E. Davies, S. Liu, S. Lewis, B. Spongberg-Ross, and K. J. Bell. Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: Protocol for an online randomised study. BMJ Open 14, no. 12 (2024): e089558. https://dx.doi.org/10.1136/bmjopen-2024-089558.
Tawbi, H. A., F. S. Hodi, E. J. Lipson, D. Schadendorf, P. A. Ascierto, L. Matamala, E. Castillo Gutierrez, P. Rutkowski, H. Gogas, C. D. Lao, J. Janoski De Menezes, S. Dalle, A. M. Arance, J. J. Grob, B. Ratto, S. Rodriguez, A. Mazzei, S. Dolfi, and G. V. Long. Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047. J Clin Oncol 43, no. 13 (2025): 1546–52. https://dx.doi.org/10.1200/JCO.24.01124.
Handel, E. E., J. McKeown, J. Wei, R. A. Kankaria, H. Burnette, D. B. Johnson, A. Lawless, J. Czapla, R. J. Sullivan, L. J. Albrecht, L. Zimmer, J. Mangana, R. Dummer, J. I. Kessels, B. Neyns, C. Allayous, C. Lebbe, C. Boatwright, J. M. Mehnert, M. Ottaviano, P. A. Ascierto, A. M. Czarnecka, P. Rutkowski, S. N. Lo, G. V. Long, A. M. Menzies, and M. S. Carlino. Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma. Eur J Cancer 215 (2025): 115171. https://dx.doi.org/10.1016/j.ejca.2024.115171.
2024
Gide, T. N., Y. Mao, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Tissue-based profiling techniques to achieve precision medicine in cancer: Opportunities and challenges in melanoma." Clin Cancer Res 30, no. 23 (Dec 2024): 5270–80. https://dx.doi.org/10.1158/1078-0432.CCR-24-1109.
Lim, S. Y., I. P. da Silva, N. A. Adegoke, S. N. Lo, A. M. Menzies, M. S. Carlino, R. A. Scolyer, G. V. Long, J. H. Lee, and H. Rizos. "Size matters: Integrating tumour volume and immune activation signatures predicts immunotherapy response." Mol Cancer 23, no. 1 (Oct 2024): 228. https://dx.doi.org/10.1186/s12943-024-02146-0.
Quek, C., A. Pratapa, X. Bai, G. Al-Eryani, I. P. da Silva, A. Mayer, N. Bartonicek, K. Harvey, N. G. Maher, J. W. Conway, R. J. Kasalo, B. Ben Cheikh, O. Braubach, U. Palendira, R. P. M. Saw, J. R. Stretch, K. F. Shannon, A. M. Menzies, R. A. Scolyer, G. V. Long, A. Swarbrick, and J. S. Wilmott. "Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy." Cell Rep 43, no. 7 (Jul 2024): 114392. https://dx.doi.org/10.1016/j.celrep.2024.114392.
da Silva, I. P., I. Li, S. Ugurel, P. Serra-Bellver, A. Andhale, H. Burnette, F. Aya, J. W. Conway, J. Braden, M. S. Carlino, A. M. Menzies, M. Weichenthal, P. Mohr, R. Gutzmer, A. M. Arance, D. B. Johnson, P. Lorigan, D. Schadendorf, S. N. Lo, and G. V. Long. "Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases." Eur J Cancer 205, no. 1 (Jul 2024): 114101. https://dx.doi.org/10.1016/j.ejca.2024.114101.
Bai, X., G. H. Attrill, T. N. Gide, P. M. Ferguson, K. J. Nahar, P. Shang, I. A. Vergara, U. Palendira, I. P. da Silva, M. S. Carlino, A. M. Menzies, G. V. Long, R. A. Scolyer, J. S. Wilmott, and C. Quek. "Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma." Nat Commun 15, no. 1 (Apr 2024): 3014. https://dx.doi.org/10.1038/s41467-024-47301-9.
Maher, N. G., I. A. Vergara, G. V. Long, and R. A. Scolyer. "Prognostic and predictive biomarkers in melanoma." Pathology 56, no. 2 (Mar 2024): 259–73. https://dx.doi.org/10.1016/j.pathol.2023.11.004.
Rogiers, A., F. Dimitriou, I. Lobon, C. Harvey, I. A. Vergara, I. P. da Silva, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, and G. V. Long. "Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy." Eur J Cancer 198, no. 113506 (Feb 2024): 113506. https://dx.doi.org/10.1016/j.ejca.2023.113506.
2023
Bai, X., A. Shaheen, C. Grieco, P. D. d'Arienzo, F. Mina, J. A. Czapla, A. R. Lawless, E. Bongiovanni, U. Santaniello, H. Zappi, D. Dulak, A. Williamson, R. Lee, A. Gupta, C. Li, L. Si, M. Ubaldi, N. Yamazaki, D. Ogata, R. Johnson, B. C. Park, S. Jung, G. Madonna, J. Hochherz, Y. Umeda, Y. Nakamura, C. Gebhardt, L. Festino, M. Capone, P. A. Ascierto, D. B. Johnson, S. N. Lo, G. V. Long, A. M. Menzies, K. Namikawa, M. Mandala, J. Guo, P. Lorigan, Y. G. Najjar, A. Haydon, P. Quaglino, G. M. Boland, R. J. Sullivan, A. J. S. Furness, R. Plummer, and K. T. Flaherty. "Dabrafenib plus trametinib versus anti-PD-1 monotherapy as adjuvant therapy in BRAF V600-mutant stage III melanoma after definitive surgery: A multicenter, retrospective cohort study." EClinicalMedicine 65, no. 102290 (Nov 2023): 102290. https://dx.doi.org/10.1016/j.eclinm.2023.102290.
Simpson, R. C., E. R. Shanahan, R. A. Scolyer, and G. V. Long. "Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors." Nat Rev Clin Oncol 20, no. 10 (Oct 2023): 697–715. https://dx.doi.org/10.1038/s41571-023-00803-9.
Conway, J. W., J. Braden, S. N. Lo, R. A. Scolyer, M. S. Carlino, A. M. Menzies, G. V. Long, and I. P. da Silva. "VEGF inhibitors improve survival outcomes in patients with liver metastases across cancer types – a meta-analysis." Cancers (Basel) 15, no. 20 (Oct 2023): 5012. https://dx.doi.org/10.3390/cancers15205012.
Gide, T. N., E. C. Paver, Z. Yaseen, N. Maher, N. Adegoke, A. M. Menzies, I. P. da Silva, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "LAG-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-LAG-3 plus anti-PD-1-based immunotherapies." Oncoimmunology 12, no. 1 (Oct 2023): 2261248. https://dx.doi.org/10.1080/2162402X.2023.2261248.
Adegoke, N. A., T. N. Gide, Y. Mao, C. Quek, E. Patrick, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, I. A. Vergara, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies." J Immunother Cancer 11, no. 10 (Oct 2023): e007144. https://dx.doi.org/10.1136/jitc-2023-007144.
Shteinman, E. R., I. A. Vergara, R. V. Rawson, S. N. Lo, N. Maeda, K. Koyama, I. P. da Silva, G. V. Long, R. A. Scolyer, J. S. Wilmott, and A. M. Menzies. "Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma." Pathology 55, no. 5 (Aug 2023): 629–36. https://dx.doi.org/10.1016/j.pathol.2023.03.007.
Lee, H., A. L. Ferguson, C. Quek, I. A. Vergara, I. P. da Silva, R. Allen, T. N. Gide, J. W. Conway, L. T. Koufariotis, N. K. Hayward, N. Waddell, M. S. Carlino, A. M. Menzies, R. P. M. Saw, E. Shklovskaya, H. Rizos, S. Lo, R. A. Scolyer, G. V. Long, U. Palendira, and J. S. Wilmott. "Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy." Clin Cancer Res 29, no. 13 (Jul 2023): 2513–24. https://dx.doi.org/10.1158/1078-0432.CCR-22-2657.
Versluis, J. M., A. M. Menzies, K. Sikorska, E. A. Rozeman, R. P. M. Saw, W. J. van Houdt, H. Eriksson, W. M. C. Klop, S. Ch'ng, J. V. van Thienen, H. Mallo, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, A. van der Wal, A. Bruining, B. A. van de Wiel, R. A. Scolyer, J. B. A. G. Haanen, T. N. Schumacher, A. C. J. van Akkooi, G. V. Long, and C. U. Blank. "Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials." Ann Oncol 34, no. 4 (Apr 2023): 420–30. https://dx.doi.org/10.1016/j.annonc.2023.01.004.
Mao, Y., T. N. Gide, N. A. Adegoke, C. Quek, N. Maher, A. Potter, E. Patrick, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, M. S. Carlino, S. N. Lo, A. M. Menzies, I. P. da Silva, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach." J Transl Med 21, no. 1 (Apr 2023): 257. https://dx.doi.org/10.1186/s12967-023-04092-9.
Wilmott, J. S., H. Tawbi, J. A. Engh, N. M. Amankulor, B. Shivalingam, H. Banerjee, I. A. Vergara, H. Lee, P. A. Johansson, P. M. Ferguson, P. Saiag, C. Robert, J. J. Grob, L. H. Butterfield, R. A. Scolyer, J. M. Kirkwood, G. V. Long, and M. A. Davies. "Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases." Clin Cancer Res 29, no. 3 (Feb 2023): 521–31. https://dx.doi.org/10.1158/1078-0432.CCR-22-2581.
2022
Rawson, R. V., E. R. Shteinman, S. Ansar, I. A. Vergara, J. F. Thompson, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Diagnostic utility of PRAME, p53, and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars, and other histological mimics." Pathology 54, no. 7 (Dec 2022): 863–73. https://dx.doi.org/10.1016/j.pathol.2022.05.012.
Newell, F., P. A. Johansson, J. S. Wilmott, K. Nones, V. Lakis, A. L. Pritchard, S. N. Lo, R. V. Rawson, S. H. Kazakoff, A. J. Colebatch, L. T. Koufariotis, P. M. Ferguson, S. Wood, C. Leonard, M. H. Law, K. M. Brooks, N. Broit, J. M. Palmer, K. L. Couts, I. A. Vergara, G. V. Long, A. P. Barbour, O. E. Nieweg, B. Shivalingam, W. A. Robinson, J. R. Stretch, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. F. Thompson, G. J. Mann, J. V. Pearson, R. A. Scolyer, N. Waddell, and N. K. Hayward. "Comparative genomics provides etiologic and biological insight into melanoma subtypes." Cancer Discov 12, no. 12 (Dec 2022): 2856–79. https://dx.doi.org/10.1158/2159-8290.CD-22-0603.
Simpson, R. C., E. R. Shanahan, M. Batten, I. L. M. Reijers, M. Read, I. P. da Silva, J. M. Versluis, R. Ribeiro, A. S. Angelatos, J. Tan, C. Adhikari, A. M. Menzies, R. P. M. Saw, M. Gonzalez, K. F. Shannon, A. J. Spillane, R. Velickovic, A. J. Lazar, A. V. Damania, A. K. Mishra, M. Chelvanambi, A. Banerjee, N. J. Ajami, J. A. Wargo, L. Macia, A. J. Holmes, J. S. Wilmott, C. U. Blank, R. A. Scolyer, and G. V. Long. "Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome." Nat Med 28, no. 11 (Nov 2022): 2344–52. https://dx.doi.org/10.1038/s41591-022-01965-2.
Conway, J. W., J. Braden, J. S. Wilmott, R. A. Scolyer, G. V. Long, and I. P. da Silva. "The effect of organ-specific tumor microenvironments on response patterns to immunotherapy." Front Immunol 13 (Nov 2022): 1030147. https://dx.doi.org/10.3389/fimmu.2022.1030147.
Nahar, K. J., F. Marsh-Wakefield, R. V. Rawson, T. N. Gide, A. L. Ferguson, R. Allen, C. Quek, I. P. da Silva, S. Tattersal, C. J. Kiely, N. Sandanayake, M. S. Carlino, G. McCaughan, J. S. Wilmott, R. A. Scolyer, G. V. Long, A. M. Menzies, and U. Palendira. "Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis." JCI Insight 7, no. 21 (Nov 2022): e157839. https://dx.doi.org/10.1172/jci.insight.157839.
Shteinman, E. R., J. S. Wilmott, I. P. da Silva, G. V. Long, R. A. Scolyer, and I. A. Vergara. "Causes, consequences, and clinical significance of aneuploidy across melanoma subtypes." Front Oncol 12 (Oct 2022): 988691. https://dx.doi.org/10.3389/fonc.2022.988691.
Conway, J. W., R. V. Rawson, S. Lo, T. Ahmed, I. A. Vergara, T. N. Gide, G. H. Attrill, M. S. Carlino, R. P. M. Saw, J. F. Thompson, A. J. Spillane, K. F. Shannon, B. Shivalingam, A. M. Menzies, J. S. Wilmott, G. V. Long, R. A. Scolyer, and I. P. da Silva. "Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites." J Immunother Cancer 10, no. 9 (Sep 2022): e004884. https://dx.doi.org/10.1136/jitc-2022-004884.
Attrill, G. H., H. Lee, A. T. Tasker, N. A. Adegoke, A. L. Ferguson, I. P. da Silva, R. P. M. Saw, J. F. Thompson, U. Palendira, G. V. Long, P. M. Ferguson, R. A. Scolyer, and J. S. Wilmott. "Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome." Front Immunol 13 (Aug 2022): 979993. https://dx.doi.org/10.3389/fimmu.2022.979993.
Colebatch, A. J., E. C. Paver, I. A. Vergara, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Elevated non-coding promoter mutations are associated with malignant transformation of melanocytic naevi to melanoma." Pathology 54, no. 5 (Aug 2022): 533–40. https://dx.doi.org/10.1016/j.pathol.2021.12.289.
Colebatch, A. J., C. Adhikari, R. J. Diefenbach, R. V. Rawson, P. M. Ferguson, H. Rizos, G. V. Long, S. W. McCarthy, J. F. Thompson, J. S. Wilmott, and R. A. Scolyer. "Comprehensive clinical, histopathologic, and molecular analysis and long-term follow-up of patients with nodal blue nevi." Am J Surg Pathol 46, no. 8 (Aug 2022): 1048–59. https://dx.doi.org/10.1097/PAS.0000000000001902.
Reijers, I. L. M., A. M. Menzies, A. C. J. van Akkooi, J. M. Versluis, N. M. J. van den Heuvel, R. P. M. Saw, T. E. Pennington, E. Kapiteijn, A. A. M. van der Veldt, K. P. M. Suijkerbuijk, G. A. P. Hospers, E. A. Rozeman, W. M. C. Klop, W. J. van Houdt, K. Sikorska, J. A. van der Hage, D. J. Grunhagen, M. W. Wouters, A. J. Witkamp, C. L. Zuur, J. M. Lijnsvelt, A. Torres Acosta, L. G. Grijpink-Ongering, M. Gonzalez, K. Jozwiak, C. Bierman, K. F. Shannon, S. Ch'ng, A. J. Colebatch, A. J. Spillane, J. B. A G. Haanen, R. V. Rawson, B. A. van de Wiel, L. V. van de Poll-Franse, R. A. Scolyer, A. H. Boekhout, G. V. Long, and C. U. Blank. "Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: The PRADO trial." Nat Med 28, no. 6 (Jun 2022): 1178–88. https://dx.doi.org/10.1038/s41591-022-01851-x.
Attrill, G. H., C. N. Owen, T. Ahmed, I. A. Vergara, A. J. Colebatch, J. W. Conway, K. J. Nahar, J. F. Thompson, I. P. da Silva, M. S. Carlino, A. M. Menzies, S. Lo, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy." J Immunother Cancer 10, no. 6 (Jun 2022): e004771. https://dx.doi.org/10.1136/jitc-2022-004771.
Yaseen, Z., T. N. Gide, J. W. Conway, A. J. Potter, C. Quek, A. M. Hong, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Validation of an accurate automated multiplex immunofluorescence method for immuno-profiling melanoma." Front Mol Biosci 9 (May 2022): 810858. https://dx.doi.org/10.3389/fmolb.2022.810858.
da Silva, I. P., T. Ahmed, J. L. McQuade, C. A. Nebhan, J. J. Park, J. M. Versluis, P. Serra-Bellver, Y. Khan, T. Slattery, H. K. Oberoi, S. Ugurel, L. E. Haydu, R. Herbst, J. Utikal, C. Pfohler, P. Terheyden, M. Weichenthal, R. Gutzmer, P. Mohr, R. Rai, J. L. Smith, R. A. Scolyer, A. M. Arance, L. Pickering, J. Larkin, P. Lorigan, C. U. Blank, D. Schadendorf, M. A. Davies, M. S. Carlino, D. B. Johnson, G. V. Long, S. N. Lo, and A. M. Menzies. "Clinical models to define response and survival with anti-PD-1 antibodies alone or combined with ipilimumab in metastatic melanoma." J Clin Oncol 40, no. 10 (Apr 2022): 1068–80. https://dx.doi.org/10.1200/JCO.21.01701.
Newell, F., I. P. da Silva, P. A. Johansson, A. M. Menzies, J. S. Wilmott, V. Addala, M. S. Carlino, H. Rizos, K. Nones, J. J. Edwards, V. Lakis, S. H. Kazakoff, P. Mukhopadhyay, P. M. Ferguson, C. Leonard, L. T. Koufariotis, S. Wood, C. U. Blank, J. F. Thompson, A. J. Spillane, R. P. M. Saw, K. F. Shannon, J. V. Pearson, G. J. Mann, N. K. Hayward, R. A. Scolyer, N. Waddell, and G. V. Long. "Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance." Cancer Cell 40, no. 1 (Jan 2022): 88–102. https://dx.doi.org/10.1016/j.ccell.2021.11.012.
Vergara, I. A., J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Genetic drivers of non-cutaneous melanomas: Challenges and opportunities in a heterogeneous landscape." Exp Dermatol 31, no. 1 (Jan 2022): 13–30. https://dx.doi.org/10.1111/exd.14287.
2021
Quek, C., X. Bai, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "High-dimensional single-cell transcriptomics in melanoma and cancer immunotherapy." Genes (Basel) 12, no. 10 (Oct 2021): 1629. https://dx.doi.org/10.3390/genes12101629.
Haas, L., A. Elewaut, C. L. Gerard, C. Umkehrer, L. Leiendecker, M. Pedersen, I. Krecioch, D. Hoffmann, M. Novatchkova, M. Kuttke, T. Neumann, I. P. da Silva, H. Witthock, M. A. Cuendet, S. Carotta, K. J. Harrington, J. Zuber, R. A. Scolyer, G. V. Long, J. S. Wilmott, O. Michielin, S. Vanharanta, T. Wiesner, and A. C. Obenauf. "Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma." Nat Cancer 2, no. 7 (Jul 2021): 693–708. https://dx.doi.org/10.1038/s43018-021-00221-9.
Gide, T. N., I. P. da Silva, C. Quek, P. M. Ferguson, M. Batten, P. Shang, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Clinical and molecular heterogeneity in patients with innate resistance to anti-PD-1+/– anti-CTLA-4 immunotherapy in metastatic melanoma reveals distinct therapeutic targets." Cancers (Basel) 13, no. 13 (Jun 2021): 3186. https://dx.doi.org/10.3390/cancers13133186.
Wu, S. Z., D. L. Roden, G. Al-Eryani, N. Bartonicek, K. Harvey, A. S. Cazet, C. L. Chan, S. Junankar, M. N. Hui, E. A. Millar, J. Beretov, L. Horvath, A. M. Joshua, P. Stricker, J. S. Wilmott, C. Quek, G. V. Long, R. A. Scolyer, B. Z. Yeung, D. Segara, C. Mak, S. Warrier, J. E. Powell, S. O'Toole, E. Lim, and A. Swarbrick. "Cryopreservation of human cancers conserves tumour heterogeneity for single-cell multi-omics analysis." Genome Med 13, no. 1 (May 2021): 81. https://dx.doi.org/10.1186/s13073-021-00885-z.
Attrill, G. H., P. M. Ferguson, U. Palendira, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "The tumour immune landscape and its implications in cutaneous melanoma." Pigment Cell Melanoma Res 34, no. 3 (May 2021): 529–49. https://dx.doi.org/10.1111/pcmr.12926.
Lee, H., I. P. da Silva, U. Palendira, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Targeting NK cells to enhance melanoma response to immunotherapies." Cancers (Basel) 13, no. 6 (Mar 2021): 1363. https://dx.doi.org/10.3390/cancers13061363.
Rozeman, E. A., E. P. Hoefsmit, I. L. M. Reijers, R. P. M. Saw, J. M. Versluis, O. Krijgsman, P. Dimitriadis, K. Sikorska, B. A. van de Wiel, H. Eriksson, M. Gonzalez, A. Torres Acosta, L. G. Grijpink-Ongering, K. Shannon, J. B. A. G. Haanen, J. Stretch, S. Ch'ng, O. E. Nieweg, H. A. Mallo, S. Adriaansz, R. M. Kerkhoven, S. Cornelissen, A. Broeks, W. M. C. Klop, C. L. Zuur, W. J. van Houdt, D. S. Peeper, A. J. Spillane, A. C. J. van Akkooi, R. A. Scolyer, T. N. M. Schumacher, A. M. Menzies, G. V. Long, and C. U. Blank. "Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma." Nat Med 27, no. 2 (Feb 2021): 256–63. https://dx.doi.org/10.1038/s41591-020-01211-7.
Simpson, R. C., E. Shanahan, R. A. Scolyer, and G. V. Long. "Targeting the microbiome to overcome resistance." Cancer Cell 39, no. 2 (Feb 2021): 151–53. https://dx.doi.org/10.1016/j.ccell.2021.01.016.
2020
Hoefsmit, E. P., E. A. Rozeman, T. M. Van, P. Dimitriadis, O. Krijgsman, J. W. Conway, I. P. da Silva, J. E. van der Wal, S. L. C. Ketelaars, K. Bresser, A. Broeks, R. M. Kerkhoven, J. W. Reeves, S. Warren, P. Kvistborg, R. A. Scolyer, E. W. Kapiteijn, D. S. Peeper, G. V. Long, T. N. M. Schumacher, and C. U. Blank. "Comprehensive analysis of cutaneous and uveal melanoma liver metastases." J Immunother Cancer 8, no. 2 (Dec 2020): e001501. https://dx.doi.org/10.1136/jitc-2020-001501.
Edwards, J., P. M. Ferguson, S. N. Lo, I. P. da Silva, A. J. Colebatch, H. Lee, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, F. Newell, J. V. Pearson, N. Waddell, N. K. Hayward, P. A. Johansson, G. J. Mann, R. A. Scolyer, U. Palendira, and J. S. Wilmott. "Tumor mutation burden and structural chromosomal aberrations are not associated with T-cell density or patient survival in acral, mucosal, and cutaneous melanomas." Cancer Immunol Res 8, no. 11 (Nov 2020): 1346–53. https://dx.doi.org/10.1158/2326-6066.CIR-19-0835.
Gide, T. N., I. P. da Silva, C. Quek, T. Ahmed, A. M. Menzies, M. S. Carlino, R. P. M. Saw, J. F. Thompson, M. Batten, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients." Oncoimmunology 9, no. 1 (Oct 2020): 1659093. https://dx.doi.org/10.1080/2162402X.2019.1659093.
Bailey, M. H., W. U. Meyerson, L. J. Dursi, L. B. Wang, G. Dong, W. W. Liang, A. Weerasinghe, S. Li, Y. Li, S. Kelso, The MC3 Working Group, PCAWG Novel Somatic Mutation Calling Methods Working Group, G. Saksena, K. Ellrott, M. C. Wendl, D. A. Wheeler, G. Getz, J. T. Simpson, M. B. Gerstein, L. Ding, and PCWAG Consortium. "Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples." Nat Commun 11, no. 1 (Sep 2020): 4748. https://dx.doi.org/10.1038/s41467-020-18151-y.
Li, C. H., S. D. Prokopec, R. X. Sun, F. Yousif, N. Schmitz, PCAWG Tumour Subtypes and Clinical Translation, P. C. Boutros, and PCAWG Consortium. "Sex differences in oncogenic mutational processes." Nat Commun 11, no. 1 (Aug 2020): 4330. https://dx.doi.org/10.1038/s41467-020-17359-2.
McKelvey, K. J., A. L. Hudson, R. Prasanna Kumar, J. S. Wilmott, G. H. Attrill, G. V. Long, R. A. Scolyer, S. J. Clarke, H. R. Wheeler, C. I. Diakos, and V. M. Howell. "Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model." PLoS One 15, no. 4 (Apr 2020): e0226444. https://dx.doi.org/10.1371/journal.pone.0226444.
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. "Pan-cancer analysis of whole genomes." Nature 578, no. 7793 (Feb 2020): 82–93. https://dx.doi.org/10.1038/s41586-020-1969-6.
da Silva, I. P., S. Lo, C. Quek, M. Gonzalez, M. S. Carlino, G. V. Long, and A. M. Menzies. "Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy." Cancer 126, no. 1 (Jan 2020): 86–97. https://dx.doi.org/10.1002/cncr.32522.
House, I. G., P. Savas, J. Lai, A. X. Y. Chen, A. J. Oliver, Z. L. Teo, K. L. Todd, M. A. Henderson, L. Giuffrida, E. V. Petley, K. Sek, S. Mardiana, T. N. Gide, C. Quek, R. A. Scolyer, G. V. Long, J. S. Wilmott, S. Loi, P. K. Darcy, and P. A. Beavis. "Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade." Clin Cancer Res 26, no. 2 (Jan 2020): 487–504. https://dx.doi.org/10.1158/1078-0432.CCR-19-1868.
2019
Lee, H., C. Quek, I. P. da Silva, A. Tasker, M. Batten, H. Rizos, S. Y. Lim, T. Nur Gide, P. Shang, G. H. Attrill, J. Madore, J. Edwards, M. S. Carlino, A. Guminski, R. P. M. Saw, J. F. Thompson, P. M. Ferguson, U. Palendira, A. M. Menzies, G. V. Long, R. A. Scolyer, and J. S. Wilmott. "Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients." Oncoimmunology 8, no. 2 (Oct 2019): e1537581. https://dx.doi.org/10.1080/2162402X.2018.1537581.
Colebatch, A. J., P. Ferguson, F. Newell, S. H. Kazakoff, T. Witkowski, A. Dobrovic, P. A. Johansson, R. P. M. Saw, J. R. Stretch, G. A. McArthur, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, N. Waddell, R. A. Scolyer, and J. S. Wilmott. "Molecular genomic profiling of melanocytic nevi." J Invest Dermatol 139, no. 8 (Aug 2019): 1762–68. https://dx.doi.org/10.1016/j.jid.2018.12.033.
Rozeman, E. A., A. M. Menzies, A. C. J. van Akkooi, C. Adhikari, C. Bierman, B. A. van de Wiel, R. A. Scolyer, O. Krijgsman, K. Sikorska, H. Eriksson, A. Broeks, J. V. van Thienen, A. D. Guminski, A. T. Acosta, S. Ter Meulen, A. M. Koenen, L. J. W. Bosch, K. Shannon, L. M. Pronk, M. Gonzalez, S. Ch'ng, L. G. Grijpink-Ongering, J. Stretch, S. Heijmink, H. van Tinteren, J. B. A. G. Haanen, O. E. Nieweg, W. M. C. Klop, C. L. Zuur, R. P. M. Saw, W. J. van Houdt, D. S. Peeper, A. J. Spillane, J. Hansson, T. N. Schumacher, G. V. Long, and C. U. Blank. "Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): A multicentre, phase 2, randomised, controlled trial." Lancet Oncol 20, no. 7 (Jul 2019): 948–60. https://dx.doi.org/10.1016/S1470-2045(19)30151-2.
da Silva, I. P., I. C. Glitza, L. E. Haydu, R. Johnpulle, P. D. Banks, G. D. Grass, S. M. A. Goldinger, J. L. Smith, A. S. Everett, P. Koelblinger, R. Roberts-Thomson, M. Millward, V. G. Atkinson, A. Guminski, R. Kapoor, R. M. Conry, M. S. Carlino, W. Wang, M. J. Shackleton, Z. Eroglu, S. N. Lo, A. M. Hong, G. V. Long, D. B. Johnson, and A. M. Menzies. "Incidence, features, and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies." Pigment Cell Melanoma Res 32, no. 4 (Jul 2019): 553–63. https://dx.doi.org/10.1111/pcmr.12775.
Edwards, J., A. Tasker, I. P. da Silva, C. Quek, M. Batten, A. Ferguson, R. Allen, B. Allanson, R. P. M. Saw, J. F. Thompson, A. M. Menzies, U. Palendira, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Prevalence and cellular distribution of novel immune checkpoint targets across longitudinal specimens in treatment-naive melanoma patients: Implications for clinical trials." Clin Cancer Res 25, no. 11 (Jun 2019): 3247–58. https://dx.doi.org/10.1158/1078-0432.CCR-18-4011.
Gide, T. N., B. M. Allanson, A. M. Menzies, P. M. Ferguson, J. Madore, R. P. M. Saw, J. F. Thompson, G. V. Long, J. S. Wilmott, and R. A. Scolyer. "Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment." Histopathology 74, no. 6 (May 2019): 817–28. https://dx.doi.org/10.1111/his.13814.
Wilmott, J. S., P. A. Johansson, F. Newell, N. Waddell, P. Ferguson, C. Quek, A. M. Patch, K. Nones, P. Shang, A. L. Pritchard, S. Kazakoff, O. Holmes, C. Leonard, S. Wood, Q. Xu, R. P. M. Saw, A. J. Spillane, J. R. Stretch, K. F. Shannon, R. F. Kefford, A. M. Menzies, G. V. Long, J. F. Thompson, J. V. Pearson, G. J. Mann, N. K. Hayward, and R. A. Scolyer. "Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility." Int J Cancer 144, no. 5 (Mar 2019): 1049–60. https://dx.doi.org/10.1002/ijc.31791.
Lim, S. Y., J. H. Lee, T. N. Gide, A. M. Menzies, A. Guminski, M. S. Carlino, E. J. Breen, J. Y. H. Yang, S. Ghazanfar, R. F. Kefford, R. A. Scolyer, G. V. Long, and H. Rizos. "Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy." Clin Cancer Res 25, no. 5 (Mar 2019): 1557–63. https://dx.doi.org/10.1158/1078-0432.CCR-18-2795.
Gide, T. N., C. Quek, A. M. Menzies, A. T. Tasker, P. Shang, J. Holst, J. Madore, S. Y. Lim, R. Velickovic, M. Wongchenko, Y. Yan, S. N. Lo, M. S. Carlino, A. Guminski, R. P. M. Saw, A. Pang, H. M. McGuire, U. Palendira, J. F. Thompson, H. Rizos, I. P. da Silva, M. Batten, R. A. Scolyer, G. V. Long, and J. S. Wilmott. "Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1/anti-CTLA-4 combined therapy." Cancer Cell 35, no. 2 (Feb 2019): 238–55. https://dx.doi.org/10.1016/j.ccell.2019.01.003.
da Silva, I. P., K. Y. X. Wang, J. S. Wilmott, J. Holst, M. S. Carlino, J. J. Park, C. Quek, M. Wongchenko, Y. Yan, G. Mann, D. B. Johnson, J. L. McQuade, R. Rai, R. F. Kefford, H. Rizos, R. A. Scolyer, J. Y. H. Yang, G. V. Long, and A. M. Menzies. "Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma." Clin Cancer Res 25, no. 4 (Feb 2019): 1272–79. https://dx.doi.org/10.1158/1078-0432.CCR-18-1680.
Quek, C., R. V. Rawson, P. M. Ferguson, P. Shang, I. P. da Silva, R. P. M. Saw, K. Shannon, J. F. Thompson, N. K. Hayward, G. V. Long, G. J. Mann, R. A. Scolyer, and J. S. Wilmott. "Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas." Oncotarget 10, no. 9 (Jan 2019): 930–41. https://dx.doi.org/10.18632/oncotarget.26584.
2018
Korkut, A., S. Zaidi, R. S. Kanchi, S. Rao, N. R. Gough, A. Schultz, X. Li, P. L. Lorenzi, A. C. Berger, G. Robertson, L. N. Kwong, M. Datto, J. Roszik, S. Ling, V. Ravikumar, G. Manyam, A. Rao, S. Shelley, Y. Liu, Z. Ju, D. Hansel, G. de Velasco, A. Pennathur, J. B. Andersen, C. J. O'Rourke, K. Ohshiro, W. Jogunoori, B. N. Nguyen, S. Li, H. U. Osmanbeyoglu, J. A. Ajani, S. A. Mani, A. Houseman, M. Wiznerowicz, J. Chen, S. Gu, W. Ma, J. Zhang, P. Tong, A. D. Cherniack, C. Deng, L. Resar, Cancer Genome Atlas Research Network, J. N. Weinstein, L. Mishra, and R. Akbani. "A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-beta superfamily." Cell Syst 7, no. 4 (Oct 2018): 422–37. https://dx.doi.org/10.1016/j.cels.2018.08.010.
Edwards, J., J. S. Wilmott, J. Madore, T. N. Gide, C. Quek, A. Tasker, A. Ferguson, J. Chen, R. Hewavisenti, P. Hersey, T. Gebhardt, W. Weninger, W. J. Britton, R. P. M. Saw, J. F. Thompson, A. M. Menzies, G. V. Long, R. A. Scolyer, and U. Palendira. "CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment." Clin Cancer Res 24, no. 13 (Jul 2018): 3036–45. https://dx.doi.org/10.1158/1078-0432.CCR-17-2257.
Long, G. V., V. Atkinson, S. Lo, S. Sandhu, A. D. Guminski, M. P. Brown, J. S. Wilmott, J. Edwards, M. Gonzalez, R. A. Scolyer, A. M. Menzies, and G. A. McArthur. "Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: A multicentre randomised phase 2 study." Lancet Oncol 19, no. 5 (May 2018): 672–81. https://dx.doi.org/10.1016/S1470-2045(18)30139-6.
Bailey, M. H., C. Tokheim, E. Porta-Pardo, S. Sengupta, D. Bertrand, A. Weerasinghe, A. Colaprico, M. C. Wendl, J. Kim, B. Reardon, P. K. Ng, K. J. Jeong, S. Cao, Z. Wang, J. Gao, Q. Gao, F. Wang, E. M. Liu, L. Mularoni, C. Rubio-Perez, N. Nagarajan, I. Cortes-Ciriano, D. C. Zhou, W. W. Liang, J. M. Hess, V. D. Yellapantula, D. Tamborero, A. Gonzalez-Perez, C. Suphavilai, J. Y. Ko, E. Khurana, P. J. Park, E. M. van Allen, H. Liang, The MC3 Working Group, Cancer Genome Atlas Research Network, M. S. Lawrence, A. Godzik, N. Lopez-Bigas, J. Stuart, D. Wheeler, G. Getz, K. Chen, A. J. Lazar, G. B. Mills, R. Karchin, and L. Ding. "Comprehensive characterization of cancer driver genes and mutations." Cell 173, no. 2 (Apr 2018): 371–85. https://dx.doi.org/10.1016/j.cell.2018.02.060.
Ding, L., M. H. Bailey, E. Porta-Pardo, V. Thorsson, A. Colaprico, D. Bertrand, D. L. Gibbs, A. Weerasinghe, K. L. Huang, C. Tokheim, I. Cortes-Ciriano, R. Jayasinghe, F. Chen, L. Yu, S. Sun, C. Olsen, J. Kim, A. M. Taylor, A. D. Cherniack, R. Akbani, C. Suphavilai, N. Nagarajan, J. M. Stuart, G. B. Mills, M. A. Wyczalkowski, B. G. Vincent, C. M. Hutter, J. C. Zenklusen, K. A. Hoadley, M. C. Wendl, L. Shmulevich, A. J. Lazar, D. A. Wheeler, G. Getz, and Cancer Genome Atlas Research Network. "Perspective on oncogenic processes at the end of the beginning of cancer genomics." Cell 173, no. 2 (Apr 2018): 305–20. https://dx.doi.org/10.1016/j.cell.2018.03.033.
Ge, Z., J. S. Leighton, Y. Wang, X. Peng, Z. Chen, H. Chen, Y. Sun, F. Yao, J. Li, H. Zhang, J. Liu, C. D. Shriver, H. Hu, Cancer Genome Atlas Research Network, H. Piwnica-Worms, L. Ma, and H. Liang. "Integrated genomic analysis of the ubiquitin pathway across cancer types." Cell Rep 23, no. 1 (Apr 2018): 213–26. https://dx.doi.org/10.1016/j.celrep.2018.03.047.
Liu, J., T. Lichtenberg, K. A. Hoadley, L. M. Poisson, A. J. Lazar, A. D. Cherniack, A. J. Kovatich, C. C. Benz, D. A. Levine, A. V. Lee, L. Omberg, D. M. Wolf, C. D. Shriver, V. Thorsson, Cancer Genome Atlas Research Network, and H. Hu. "An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics." Cell 173, no. 2 (Apr 2018): 400–16. https://dx.doi.org/10.1016/j.cell.2018.02.052.
Sanchez-Vega, F., M. Mina, J. Armenia, W. K. Chatila, A. Luna, K. C. La, S. Dimitriadoy, D. L. Liu, H. S. Kantheti, S. Saghafinia, D. Chakravarty, F. Daian, Q. Gao, M. H. Bailey, W. W. Liang, S. M. Foltz, I. Shmulevich, L. Ding, Z. Heins, A. Ochoa, B. Gross, J. Gao, H. Zhang, R. Kundra, C. Kandoth, I. Bahceci, L. Dervishi, U. Dogrusoz, W. Zhou, H. Shen, P. W. Laird, G. P. Way, C. S. Greene, H. Liang, Y. Xiao, C. Wang, A. Iavarone, A. H. Berger, T. G. Bivona, A. J. Lazar, G. D. Hammer, T. Giordano, L. N. Kwong, G. McArthur, C. Huang, A. D. Tward, M. J. Frederick, F. McCormick, M. Meyerson, Cancer Genome Atlas Research Network, E. M. Van Allen, A. D. Cherniack, G. Ciriello, C. Sander, and N. Schultz. "Oncogenic signaling pathways in the cancer genome atlas." Cell 173, no. 2 (Apr 2018): 321–37. https://dx.doi.org/10.1016/j.cell.2018.03.035.
Thorsson, V., D. L. Gibbs, S. D. Brown, D. Wolf, D. S. Bortone, T. H. Ou Yang, E. Porta-Pardo, G. F. Gao, C. L. Plaisier, J. A. Eddy, E. Ziv, A. C. Culhane, E. O. Paull, I. K. A. Sivakumar, A. J. Gentles, R. Malhotra, F. Farshidfar, A. Colaprico, J. S. Parker, L. E. Mose, N. S. Vo, J. Liu, Y. Liu, J. Rader, V. Dhankani, S. M. Reynolds, R. Bowlby, A. Califano, A. D. Cherniack, D. Anastassiou, D. Bedognetti, Y. Mokrab, A. M. Newman, A. Rao, K. Chen, A. Krasnitz, H. Hu, T. M. Malta, H. Noushmehr, C. S. Pedamallu, S. Bullman, A. I. Ojesina, A. Lamb, W. Zhou, H. Shen, T. K. Choueiri, J. N. Weinstein, J. Guinney, J. Saltz, R. A. Holt, C. S. Rabkin, Cancer Genome Atlas Research Network, A. J. Lazar, J. S. Serody, E. G. Demicco, M. L. Disis, B. G. Vincent, and I. Shmulevich. "The immune landscape of cancer." Immunity 48, no. 4 (Apr 2018): 812–30. https://dx.doi.org/10.1016/j.immuni.2018.03.023.
Gide, T. N., J. S. Wilmott, R. A. Scolyer, and G. V. Long. "Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma." Clin Cancer Res 24, no. 6 (Mar 2018): 1260–70. https://dx.doi.org/10.1158/1078-0432.CCR-17-2267.
Pre-2018
Kakavand, H., L. A. Jackett, A. M. Menzies, T. N. Gide, M. S. Carlino, R. P. M. Saw, J. F. Thompson, J. S. Wilmott, G. V. Long, and R. A. Scolyer. "Negative immune checkpoint regulation by vista: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients." Mod Pathol 30, no. 12 (Dec 2017): 1666–76. https://dx.doi.org/10.1038/modpathol.2017.89.
Hayward, N. K., J. S. Wilmott, N. Waddell, P. A. Johansson, M. A. Field, K. Nones, A. M. Patch, H. Kakavand, L. B. Alexandrov, H. Burke, V. Jakrot, S. Kazakoff, O. Holmes, C. Leonard, R. Sabarinathan, L. Mularoni, S. Wood, Q. Xu, N. Waddell, V. Tembe, G. M. Pupo, R. De Paoli-Iseppi, R. E. Vilain, P. Shang, L. M. S. Lau, R. A. Dagg, S. J. Schramm, A. Pritchard, K. Dutton-Regester, F. Newell, A. Fitzgerald, C. A. Shang, S. M. Grimmond, H. A. Pickett, J. Y. Yang, J. R. Stretch, A. Behren, R. F. Kefford, P. Hersey, G. V. Long, J. Cebon, M. Shackleton, A. J. Spillane, R. P. M. Saw, N. Lopez-Bigas, J. V. Pearson, J. F. Thompson, R. A. Scolyer, and G. J. Mann. "Whole-genome landscapes of major melanoma subtypes." Nature 545, no. 7653 (May 2017): 175–80. https://dx.doi.org/10.1038/nature22071.
Cancer Genome Atlas Network. "Genomic classification of cutaneous melanoma." Cell 161, no. 7 (Jun 2015): 1681–96. https://dx.doi.org/10.1016/j.cell.2015.05.044.